Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Cash from Financing Activities: 2023-2025

Historic Cash from Financing Activities for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to $54.4 million.

  • CG Oncology's Cash from Financing Activities rose 2409.00% to $54.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $277.9 million, marking a year-over-year decrease of 30.86%. This contributed to the annual value of $628.3 million for FY2024, which is 622.18% up from last year.
  • As of Q3 2025, CG Oncology's Cash from Financing Activities stood at $54.4 million, which was up 18,468.24% from -$296,000 recorded in Q2 2025.
  • CG Oncology's Cash from Financing Activities' 5-year high stood at $402.7 million during Q1 2024, with a 5-year trough of -$15.2 million in Q2 2023.
  • Its 3-year average for Cash from Financing Activities is $70.0 million, with a median of $450,000 in 2025.
  • As far as peak fluctuations go, CG Oncology's Cash from Financing Activities spiked by 52,735.03% in 2024, and later tumbled by 840.00% in 2025.
  • CG Oncology's Cash from Financing Activities (Quarterly) stood at -$2.9 million in 2023, then surged by 7,814.57% to $223.4 million in 2024, then soared by 2,409.00% to $54.4 million in 2025.
  • Its Cash from Financing Activities stands at $54.4 million for Q3 2025, versus -$296,000 for Q2 2025 and $450,000 for Q1 2025.